{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T08:23:44Z","timestamp":1784967824175,"version":"3.55.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.clbc.2022.02.002","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T13:00:47Z","timestamp":1644238847000},"page":"289-299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-7667","authenticated-orcid":false,"given":"Fabio","family":"Canino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2906-7896","authenticated-orcid":false,"given":"Claudia","family":"Omarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisida","family":"Cerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9108-4849","authenticated-orcid":false,"given":"Luca","family":"Moscetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9609-5005","authenticated-orcid":false,"given":"Antonio","family":"Tornincasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Trudu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Dominici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8969-638X","authenticated-orcid":false,"given":"Federico","family":"Piacentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clbc.2022.02.002_bib0001","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/oxfordjournals.annonc.a058497","article-title":"Ophthalmic toxicity during carboplatin therapy","volume":"4","author":"Rankin","year":"1993","journal-title":"Ann Oncol"},{"issue":"8792","key":"10.1016\/j.clbc.2022.02.002_bib0002","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0140-6736(92)90384-F","article-title":"Blindness associated with high-dose carboplatin","volume":"339","author":"O'Brien","year":"1992","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clbc.2022.02.002_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0161-6420(83)34600-5","article-title":"Ocular toxicity of antineoplastic agents","volume":"90","author":"Fraunfelder","year":"1983","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.clbc.2022.02.002_bib0004","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/1097-0142(197907)44:1<69::AID-CNCR2820440113>3.0.CO;2-O","article-title":"Blurring of vision: a previously undescribed complication of cyclophosphamide therapy","volume":"44","author":"Kende","year":"1979","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2022.02.002_bib0005","first-page":"120","article-title":"Ocular surface and tear film abnormalities in women under adjuvant chemotherapy for breast cancer with the 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) regimen","volume":"17","author":"Karamitsos","year":"2013","journal-title":"Hippokratia"},{"key":"10.1016\/j.clbc.2022.02.002_bib0006","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/1097-0142(19811115)48:10<2158::AID-CNCR2820481007>3.0.CO;2-I","article-title":"Ocular irritation from high dose methotrexate therapy: pharmacokinetics of drug in the tear film","volume":"48","author":"Doroshow","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2022.02.002_bib0007","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/0002-9394(76)90544-4","article-title":"Optic atrophy following prophylactic chemotherapy and cranial radiation for acute lymphocytic leukemia","volume":"82","author":"Fishman","year":"1976","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clbc.2022.02.002_bib0008","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/archopht.1992.01080200130040","article-title":"Five-minute treatments with fluorouracil, floxuridine, and mitomycin have long-term effects on human Tenon's capsule fibroblasts","volume":"110","author":"Khaw","year":"1992","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.clbc.2022.02.002_bib0009","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0039-6257(89)90105-7","article-title":"Ocular complications of systemic cancer chemotherapy","volume":"34","author":"Imperia","year":"1989","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.clbc.2022.02.002_bib0010","first-page":"56","article-title":"Excessive lacrimation associated with detectable concentrations of 5-fluorouracil in tears and plasma","volume":"23","author":"Christophidis","year":"1977","journal-title":"Proc Aust Soc Clin Exp Pharmacol"},{"issue":"10","key":"10.1016\/j.clbc.2022.02.002_bib0011","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJM200009073431015","article-title":"Severe ocular irritation and corneal deposits associated with capecitabine use","volume":"343","author":"Waikhom","year":"2000","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clbc.2022.02.002_bib0012","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/archopht.118.5.726","article-title":"Purtscher retinopathy and necrotizing vasculitis with gemcitabine therapy","volume":"118","author":"Banach","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.clbc.2022.02.002_bib0013","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1755-3768.2008.01174.x","article-title":"Gemcitabine-induced retinopathy in a diabetic patient","volume":"87","author":"Tran","year":"2008","journal-title":"Acta Ophthalmol"},{"issue":"14","key":"10.1016\/j.clbc.2022.02.002_bib0014","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/jnci\/86.14.1099","article-title":"Optic nerve disturbances: a new form of paclitaxel neurotoxicity","volume":"86","author":"Capri","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.clbc.2022.02.002_bib0015","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.1994.12.8.1741","article-title":"Photopsia during 3-hour paclitaxel administration at doses >or\u00a0=\u00a0250 mg\/m2","volume":"12","author":"Seidman","year":"1994","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2022.02.002_bib0016","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/cncr.11527","article-title":"Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy","volume":"98","author":"Esmaeli","year":"2003","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clbc.2022.02.002_bib0017","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.survophthal.2014.02.004","article-title":"Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy","volume":"59","author":"Kheir","year":"2014","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"10.1016\/j.clbc.2022.02.002_bib0018","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/01.ICL.0000062464.79558.5A","article-title":"Erosive conjunctivitis and punctal stenosis secondary to docetaxel (taxotere)","volume":"29","author":"Skolnick","year":"2003","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.clbc.2022.02.002_bib0019","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10792-012-9558-9","article-title":"The mystery of angiographically silent macular oedema due to taxanes","volume":"32","author":"Kuznetcova","year":"2012","journal-title":"Int Ophthalmol"},{"issue":"3","key":"10.1016\/j.clbc.2022.02.002_bib0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/08820530701457373","article-title":"Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome","volume":"22","author":"Telander","year":"2007","journal-title":"Semin Ophthalmol"},{"issue":"2","key":"10.1016\/j.clbc.2022.02.002_bib0021","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1444-0938.2011.00672.x","article-title":"Angiographically silent cystoid macular oedema secondary to paclitaxel therapy","volume":"95","author":"Georgakopoulos","year":"2012","journal-title":"Clin Exp Optom"},{"key":"10.1016\/j.clbc.2022.02.002_bib0022","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2010.30.3750","article-title":"Cystoid macular edema secondary to nab-paclitaxel therapy","volume":"28","author":"Murphy","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9185","key":"10.1016\/j.clbc.2022.02.002_bib0023","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0140-6736(99)03019-6","article-title":"Taxane-induced glaucoma","volume":"354","author":"Fabre-Guillevin","year":"1999","journal-title":"Lancet"},{"issue":"9199","key":"10.1016\/j.clbc.2022.02.002_bib0024","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0140-6736(05)72103-6","article-title":"Glaucoma and paclitaxel (case report)","volume":"355","author":"De Giorgi","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clbc.2022.02.002_bib0025","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/ICU.0b013e32832c9007","article-title":"Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients","volume":"20","author":"Hazin","year":"2009","journal-title":"Curr Opin Ophthalmol"},{"issue":"1","key":"10.1016\/j.clbc.2022.02.002_bib0026","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ctrv.2013.05.005","article-title":"Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders","volume":"40","author":"Agustoni","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1016\/j.clbc.2022.02.002_bib0027","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/(SICI)1097-0142(19961001)78:7<1359::AID-CNCR1>3.0.CO;2-G","article-title":"Ocular toxicity and cancer chemotherapy. A review","volume":"78","author":"Al-Tweigeri","year":"1996","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.clbc.2022.02.002_bib0028","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0002-9394(89)90866-0","article-title":"Ocular adverse reactions associated with adriamycin (Doxorubicin)","volume":"108","author":"Curran","year":"1989","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.clbc.2022.02.002_bib0029","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.survophthal.2005.11.001","article-title":"Update on ocular complications of systemic cancer chemotherapy","volume":"51","author":"Schmid","year":"2006","journal-title":"Surv Ophthalmol"},{"issue":"7","key":"10.1016\/j.clbc.2022.02.002_bib0030","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/IAE.0000000000000242","article-title":"Retinal toxicities of cancer therapy drugs: biologics, small molecule inhibitors, and chemotherapies","volume":"34","author":"Liu","year":"2014","journal-title":"Retina"},{"issue":"11","key":"10.1016\/j.clbc.2022.02.002_bib0031","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/S0161-6420(00)00364-X","article-title":"Intraocular penetration of tamoxifen","volume":"107","author":"Flaxel","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clbc.2022.02.002_bib0032","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s004170050139","article-title":"Tamoxifen retinopathy: does it really exist?","volume":"236","author":"Lazzaroni","year":"1998","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.clbc.2022.02.002_bib0033","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/1097-0142(19880101)61:1<33::AID-CNCR2820610107>3.0.CO;2-I","article-title":"Reversible ocular toxicity related to tamoxifen therapy","volume":"61","author":"Ashford","year":"1988","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.clbc.2022.02.002_bib0034","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(19920615)69:12<2961::AID-CNCR2820691215>3.0.CO;2-W","article-title":"Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients","volume":"69","author":"Pavlidis","year":"1992","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clbc.2022.02.002_bib0035","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0002-9394(99)80190-1","article-title":"Long-term tamoxifen citrate use and potential ocular toxicity","volume":"125","author":"Gorin","year":"1998","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.clbc.2022.02.002_bib0036","first-page":"522","article-title":"Tamoxifen and ocular toxicity","volume":"21","author":"Ah-Song","year":"1997","journal-title":"Cancer Detect Prev"},{"issue":"10","key":"10.1016\/j.clbc.2022.02.002_bib0037","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3109\/02713683.2011.594202","article-title":"Breast cancer medications and vision: effects of treatments for early-stage disease","volume":"36","author":"Eisner","year":"2011","journal-title":"Curr Eye Res"},{"issue":"2","key":"10.1016\/j.clbc.2022.02.002_bib0038","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1600-0420.2006.00737.x","article-title":"Ocular presentations of breast cancer","volume":"85","author":"Wickremasinghe","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"issue":"9453","key":"10.1016\/j.clbc.2022.02.002_bib0039","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clbc.2022.02.002_bib0040","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/tbj.12633","article-title":"Ocular Surface Disease in Breast Cancer Patients Using Aromatase Inhibitors","volume":"22","author":"Chatziralli","year":"2016","journal-title":"Breast J"},{"key":"10.1016\/j.clbc.2022.02.002_bib0041","unstructured":"Palbociclib (Ibrance\u00a9) EMA european public assessment report. 2022."},{"key":"10.1016\/j.clbc.2022.02.002_bib0042","unstructured":"Ribociclib (Kisqali\u00a9) EMA european public assessment report. 2022."},{"key":"10.1016\/j.clbc.2022.02.002_bib0043","unstructured":"Abemaciclib (Verzenios\u00a9) EMA european public assessment report. 2022."},{"key":"10.1016\/j.clbc.2022.02.002_bib0044","unstructured":"Everolimus (Afinitor\u00a9) EMA european public assessment report. 2022."},{"issue":"26","key":"10.1016\/j.clbc.2022.02.002_bib0045","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1200\/JCO.2011.41.5851","article-title":"Ocular toxicity of targeted therapies","volume":"30","author":"Renouf","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2022.02.002_bib0046","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJM200303203481225","article-title":"Bisphosphonates and ocular inflammation","volume":"348","author":"Fraunfelder","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2022.02.002_bib0047","unstructured":"Amgen Canada Inc. Prolia (denosumab) Product Monograph. 2022"},{"issue":"7","key":"10.1016\/j.clbc.2022.02.002_bib0048","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1755-3768.2012.02518.x","article-title":"The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?","volume":"91","author":"Ho","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.clbc.2022.02.002_bib0049","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJMc052954","article-title":"Reversible posterior leukoencephalopathy syndrome and bevacizumab","volume":"354","author":"Glusker","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clbc.2022.02.002_bib0050","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/09273948.2020.1781902","article-title":"Immune checkpoint inhibitor-associated uveitis: review of treatments and outcomes","volume":"29","author":"Dow","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"10.1016\/j.clbc.2022.02.002_bib0051","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/jamaophthalmol.2018.5191","article-title":"Association of cancer immunotherapy with acute macular neuroretinopathy and diffuse retinal venulitis","volume":"137","author":"Emens","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.clbc.2022.02.002_bib0052","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.oret.2019.11.006","article-title":"Clinical and morphological characteristics of anti-programmed death ligand 1-associated retinopathy: expanding the spectrum of acute macular neuroretinopathy","volume":"4","author":"Ramtohul","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"6","key":"10.1016\/j.clbc.2022.02.002_bib0053","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.clbc.2022.02.002_bib0054","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ejca.2013.10.016","article-title":"Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review","volume":"50","author":"Huillard","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2022.02.002_bib0055","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1186\/s12885-015-1969-3","article-title":"Trastuzumab-induced corneal ulceration: successful no-drug treatment of a \"blind\" side effect in a case report","volume":"15","author":"Orlandi","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clbc.2022.02.002_bib0056","unstructured":"Trastuzumab (Herceptin\u00a9) EMA product information. 2022."},{"issue":"1","key":"10.1016\/j.clbc.2022.02.002_bib0057","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00003226-200101000-00016","article-title":"Expression of the receptor tyrosine kinases, epidermal growth factor receptor, ErbB2, and ErbB3, in human ocular surface epithelia","volume":"20","author":"Liu","year":"2001","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.clbc.2022.02.002_bib0058","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3109\/0284186X.2011.555781","article-title":"Bilateral macular ischemia and severe visual loss following trastuzumab therapy","volume":"50","author":"Saleh","year":"2011","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clbc.2022.02.002_bib0059","unstructured":"Pertuzumab (Perjeta\u00a9) EMA european public assessment report. 2022."},{"issue":"4","key":"10.1016\/j.clbc.2022.02.002_bib0060","first-page":"1045","article-title":"The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies","volume":"10","author":"Kreutzfeldt","year":"2020","journal-title":"Am J Cancer Res"},{"issue":"4","key":"10.1016\/j.clbc.2022.02.002_bib0061","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/annonc\/mdx002","article-title":"First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors","volume":"28","author":"Bang","year":"2017","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.clbc.2022.02.002_bib0062","article-title":"SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M)\u00a0+\u00a0Ctx versus trastuzumab (T)\u00a0+\u00a0Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC)","volume":"38","author":"Escriv\u00e1","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2022.02.002_bib0063","unstructured":"Lapatinib (Tyverb\u00a9) EMA european public assessment report. 2022."},{"key":"10.1016\/j.clbc.2022.02.002_bib0064","unstructured":"Neratinib (Nerlynx\u00a9) EMA european public assessment report. 2022."},{"issue":"14","key":"10.1016\/j.clbc.2022.02.002_bib0065","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1158\/1078-0432.CCR-16-1496","article-title":"Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)","volume":"23","author":"Moulder","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.clbc.2022.02.002_bib0066","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2022.02.002_bib0067","unstructured":"Trastuzumab emtasine (Kadcyla\u00a9) EMA european public assessment report. 2022"},{"issue":"23","key":"10.1016\/j.clbc.2022.02.002_bib0068","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1002\/cncr.27622","article-title":"A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer","volume":"118","author":"Beeram","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2022.02.002_bib0069","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10549-019-05179-y","article-title":"Corneal features in trastuzumab emtansine treatment: not a rare occurrence","volume":"175","author":"Deklerck","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.clbc.2022.02.002_bib0070","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.clbc.2018.03.005","article-title":"Corneal changes in Trastuzumab emtansine treatment","volume":"18","author":"Kreps","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"10","key":"10.1016\/j.clbc.2022.02.002_bib0071","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1097\/ICO.0000000000000868","article-title":"Abnormal Corneal Lesions Induced by Trastuzumab Emtansine: an antibody-drug conjugate for breast cancer","volume":"35","author":"Tsuda","year":"2016","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.clbc.2022.02.002_bib0072","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1186\/s12885-019-5986-5","article-title":"Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla\u00ae, T-DM1) administration: a case report","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.clbc.2022.02.002_bib0073","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody-drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.clbc.2022.02.002_bib0074","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clbc.2022.02.002_bib0075","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clbc.2022.02.002_bib0076","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00417-019-04337-8","article-title":"Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics","volume":"257","author":"Kunkler","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"35","key":"10.1016\/j.clbc.2022.02.002_bib0077","doi-asserted-by":"crossref","first-page":"58709","DOI":"10.18632\/oncotarget.17634","article-title":"Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions","volume":"8","author":"Fu","year":"2017","journal-title":"Oncotarget"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820922000362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820922000362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:21:59Z","timestamp":1761513719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820922000362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1526820922000362"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2022.02.002","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2022.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}